These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 16170842)

  • 1. Prenatal screening for Down syndrome and neural tube defects in twin pregnancies.
    Wald NJ; Rish S
    Prenat Diagn; 2005 Sep; 25(9):740-5. PubMed ID: 16170842
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current concepts of Down syndrome screening tests in assisted reproduction twin pregnancies: another double trouble.
    Maymon R; Neeman O; Shulman A; Rosen H; Herman A
    Prenat Diagn; 2005 Sep; 25(9):746-50. PubMed ID: 16170837
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combining nuchal translucency and serum markers in prenatal screening for Down syndrome in twin pregnancies.
    Wald NJ; Rish S; Hackshaw AK
    Prenat Diagn; 2003 Jul; 23(7):588-92. PubMed ID: 12868090
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prenatal maternal dried blood screening with alpha-fetoprotein and free beta-human chorionic gonadotropin for open neural tube defect and Down syndrome.
    Macri JN; Anderson RW; Krantz DA; Larsen JW; Buchanan PD
    Am J Obstet Gynecol; 1996 Feb; 174(2):566-72. PubMed ID: 8623786
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Screening for trisomy 21 in twins using first trimester ultrasound and maternal serum biochemistry in a one-stop clinic: a review of three years experience.
    Spencer K; Nicolaides KH
    BJOG; 2003 Mar; 110(3):276-80. PubMed ID: 12628267
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhanced twin pregnancy detection within an open neural tube defect and Down syndrome screening protocol using free-beta hCG and AFP.
    Barnabei VM; Krantz DA; Macri JN; Larsen JW
    Prenat Diagn; 1995 Dec; 15(12):1131-4. PubMed ID: 8750293
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prospective first-trimester screening for trisomy 21 in 30,564 pregnancies.
    Avgidou K; Papageorghiou A; Bindra R; Spencer K; Nicolaides KH
    Am J Obstet Gynecol; 2005 Jun; 192(6):1761-7. PubMed ID: 15970804
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Between pregnancy biological variability of first trimester markers of Down syndrome: implications for screening in subsequent pregnancies.
    Spencer K
    Prenat Diagn; 2001 Jun; 21(6):445-7. PubMed ID: 11438946
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Screening for trisomy 21 by maternal age, fetal nuchal translucency and maternal serum biochemistry at 11-14 weeks: a German multicenter study.
    von Kaisenberg CS; Gasiorek-Wiens A; Bielicki M; Bahlmann F; Meyberg H; Kossakiewicz A; Pruggmayer M; Kamin G; Fritzer E; Harris C; Arnold N;
    J Matern Fetal Neonatal Med; 2002 Aug; 12(2):89-94. PubMed ID: 12420837
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Down syndrome and neural tube defect screening: the value of using gestational age by ultrasonography.
    Benn PA; Borgida A; Horne D; Briganti S; Collins R; Rodis JF
    Am J Obstet Gynecol; 1997 May; 176(5):1056-61. PubMed ID: 9166168
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Screening for Down's syndrome--too many choices?
    Mennuti MT; Driscoll DA
    N Engl J Med; 2003 Oct; 349(15):1471-3. PubMed ID: 14534341
    [No Abstract]   [Full Text] [Related]  

  • 12. Biochemical screening for congenital defects.
    Bahado-Singh RO; Sutton-Riley J
    Obstet Gynecol Clin North Am; 2004 Dec; 31(4):857-72, xi. PubMed ID: 15550339
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A reassessment of biochemical marker distributions in trisomy 21-affected and unaffected twin pregnancies in the first trimester.
    Madsen HN; Ball S; Wright D; Tørring N; Petersen OB; Nicolaides KH; Spencer K
    Ultrasound Obstet Gynecol; 2011 Jan; 37(1):38-47. PubMed ID: 20878678
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The use of nuchal translucency in contemporary obstetric practice.
    Said S; Malone FD
    Clin Obstet Gynecol; 2008 Mar; 51(1):37-47. PubMed ID: 18303498
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A screening program for trisomy 21 at 10-14 weeks using fetal nuchal translucency, maternal serum free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A.
    Spencer K; Souter V; Tul N; Snijders R; Nicolaides KH
    Ultrasound Obstet Gynecol; 1999 Apr; 13(4):231-7. PubMed ID: 10341399
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is screening for fetal anomalies reliable in HIV-infected pregnant women? A multicentre study.
    Brossard P; Boulvain M; Coll O; Barlow P; Aebi-Popp K; Bischof P; Martinez de Tejada B; ;
    AIDS; 2008 Oct; 22(15):2013-7. PubMed ID: 18784463
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prenatal biochemical screening for Down's syndrome and neural tube defects.
    Wald NJ; Kennard A
    Curr Opin Obstet Gynecol; 1992 Apr; 4(2):302-7. PubMed ID: 1373963
    [TBL] [Abstract][Full Text] [Related]  

  • 18. One-stop clinic for assessment of risk of chromosomal defects at 12 weeks of gestation.
    Nicolaides KH; Bindra R; Heath V; Cicero S
    J Matern Fetal Neonatal Med; 2002 Jul; 12(1):9-18. PubMed ID: 12422904
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Triploidy identified through second-trimester serum screening.
    Huang T; Alberman E; Wald N; Summers AM
    Prenat Diagn; 2005 Mar; 25(3):229-33. PubMed ID: 15791661
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Uptake of prenatal screening for chromosomal anomalies: impact of test results in a previous pregnancy.
    Spencer K
    Prenat Diagn; 2002 Dec; 22(13):1229-32. PubMed ID: 12478639
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.